1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Phytohealth Corporation

Phytohealth Corporation

TTWSE:4108
11.85
TWD
+0.65
(+5.80%)
-0.44EPS
2.40BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.86
0.54
0.12
0.15
0.32
0.64
0.57
0.56
0.86
0.68
0.82
0.77
0.68
0.69
Basic EPS, GAAP
-1.09
-1.91
-1.21
-1.15
-1.22
-1.08
-1.01
-0.54
-0.4
-0.4
-0.24
-0.37
-0.29
-0.21
Free Cash Flow per Basic Share
-0.88
2.59
-0.9
-4.62
-1.14
-1.22
-0.8
-0.91
-0.42
-0.31
-0.3
-0.28
-0.23
-0.09
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
15.21
13.34
12.22
11.15
9.96
8.66
7.72
7.61
9.97
9.61
9.7
9.57
9.43
9.78
Tangible Book Value per Share
14.09
12.32
11.3
10.27
9.23
7.86
7.09
7.03
9.52
9.19
9.33
9.24
9.13
9.5
Basic Weighted Avg Shares
169
169
169
169
169
169
169
164
196
199
199
199
199
209
Sales/Revenue/Turnover
145
91
21
25
54
107
95
92
169
135
162
154
135
143
Operating Margin (%)
-165.78
-381.01
-1,270.14
-956.12
-496.99
-250.12
-214.96
-185.53
-78.26
-115.69
-74.88
-104.31
-129.73
-114.63
Depreciation Expense
48
53
49
49
50
55
65
55
53
52
53
53
49
48
Net Income, GAAP
-183
-322
-203
-195
-206
-182
-171
-88
-78
-79
-47
-74
-58
-43
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-126.19
-354.56
-970.06
-777.41
-382.16
-169.77
-178.83
-96.11
-46
-58.62
-29
-47.86
-43.25
-30.24
Working Capital
1,647
1,335
1,297
1,414
1,208
962
826
885
1,562
1,506
1,442
1,252
1,218
1,139
LT Debt
- -
- -
- -
- -
- -
- -
6
13
20
20
17
12
8
13
Total Equity
2,739
2,388
2,297
2,315
2,078
1,945
1,752
1,702
2,389
2,277
2,271
2,368
2,294
2,353
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-6.89
-13.39
-9.46
-9.87
-11.59
-11.62
-12.36
-6.82
-4.76
-4.08
-2.46
-3.84
-3.08
-2.29

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
10
9
LT Borrowings
- -
- -
- -
LT Finance Leases
8
14
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
199
199
199
Market Capitalization
2,681
2,503
2,403

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,264
1,184
1,179
Cash, Cash Equivalents & STI
1,071
1,003
1,002
Accounts Receivable, Net
36
34
35
Inventories
126
116
110
Total Current Liabilities
46
33
40
Payables & Accruals
- -
- -
- -
ST Debt
7
10
9
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.79%
7.3%
-3.16%
Free Cash Flow
22.35%
-19.59%
-17.38%
Net Income, GAAP
-7.99%
-3.05%
-20.82%
Sales/Revenue/Turnover
28.54%
13.26%
-12.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33
44
40
37
154
2025
31
31
40
33
135
2026
35
36
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.08
-0.06
-0.09
-0.37
2025
-0.07
-0.11
-0.02
-0.09
-0.29
2026
-0.08
-0.03
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
I Lin Lee
Full Time Employees
84
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.167, Fu Hsing North Road Taipei TP Taiwan 105
IPO Date
May 7, 2002
Website
phytohealth.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PhytoHealth Corporation PhytoHealth Corporation (4108.TW) researches, develops, manufactures, and sells botanical-based pharmaceuticals, cosmetics, Class B medicines, and dietary supplements, with a focus on oncology supportive care, pain relief, and innovative plant-derived treatments derived from natural plants and Chinese herbal medicine components through extraction, separation, and biochemical technologies; key products include PG2 Lyo. Injection (astragalus polysaccharides for cancer-related fatigue), Oraphine Soft Capsules (nalbuphine HCl for moderate to severe acute pain, featuring patented oral bioavailability technology with fast onset in 15-30 minutes), and refined Astragalus Polysaccharides (rAPS) for disease-targeted drug development. Incorporated in 1998 and listed on the Taiwan Stock Exchange in 2008, the company, a member of the Maywufa Biopharma Group and headquartered at 5F-1, No. 167, Fu Hsing North Road, Taipei, Taiwan, operates primarily in Taiwan with distribution to overseas markets and provides pharmaceutical consulting services for API and chemical medicine R&D. PhytoHealth maintains a PIC/S GMP and GACP-compliant manufacturing facility for botanical active pharmaceutical ingredients, adhering to TFDA and US FDA standards; recent developments include TFDA approvals for PG2 Lyo. and Oraphine, US FDA Phase II trial clearances for PG2 Lyo., PHN031, and PHN033, and ongoing partnership discussions with major European phytotherapy manufacturers to co-develop functional active ingredients for the global anti-aging health supplement market as outlined in its 2025 business plan.